Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 13.05.20 in Vol 6, No 2 (2020): Apr-Jun

This paper is in the following e-collection/theme issue:

Works citing "Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point"

According to Crossref, the following articles are citing this article (DOI 10.2196/19199):

(note that this is only a small subset of citations)

  1. Pillaiyar T, Wendt LL, Manickam M, Easwaran M. The recent outbreaks of human coronaviruses: A medicinal chemistry perspective. Medicinal Research Reviews 2020;
  2. Infante M, Ricordi C, Alejandro R, Caprio M, Fabbri A. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. Expert Review of Anti-infective Therapy 2020;:1
  3. Mostafa T. Could oral PDE-5 inhibitors have a potential adjuvant role in combating COVID-19 infection?. Sexual Medicine Reviews 2020;
  4. Lisi L, Lacal PM, Barbaccia ML, Graziani G. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Biochemical Pharmacology 2020;180:114169
  5. Heffernan KS, Ranadive SM, Jae SY. Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy. Medical Hypotheses 2020;143:110197
  6. Mondaini N. Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?. The World Journal of Men's Health 2020;38(3):254
  7. Cadegiani FA. Repurposing existing drugs for COVID-19: an endocrinology perspective. BMC Endocrine Disorders 2020;20(1)